FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016538158> ?p ?o ?g. }

• W3016538158 endingPage "1291" @default.
• W3016538158 startingPage "1278" @default.
• W3016538158 abstract "Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukaemia. Methods ELEVATE-TN is a global, phase 3, multicentre, open-label study in patients with treatment-naive chronic lymphocytic leukaemia done at 142 academic and community hospitals in 18 countries. Eligible patients had untreated chronic lymphocytic leukaemia and were aged 65 years or older, or older than 18 years and younger than 65 years with creatinine clearance of 30–69 mL/min (calculated by use of the Cockcroft-Gault equation) or Cumulative Illness Rating Scale for Geriatrics score greater than 6. Additional criteria included an Eastern Cooperative Oncology Group performance status score of 2 or less and adequate haematologic, hepatic, and renal function. Patients with significant cardiovascular disease were excluded, and concomitant treatment with warfarin or equivalent vitamin K antagonists was prohibited. Patients were randomly assigned (1:1:1) centrally via an interactive voice or web response system to receive acalabrutinib and obinutuzumab, acalabrutinib monotherapy, or obinutuzumab and oral chlorambucil. Treatments were administered in 28-day cycles. To reduce infusion-related reactions, acalabrutinib was administered for one cycle before obinutuzumab administration. Oral acalabrutinib was administered (100 mg) twice a day until progressive disease or unacceptable toxic effects occurred. In the acalabrutinib-obinutuzumab group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 2 and on day 1 (1000 mg) of cycles 3–7. In the obinutuzumab-chlorambucil group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 1 and on day 1 (1000 mg) of cycles 2–6. Oral chlorambucil was given (0·5 mg/kg) on days 1 and 15 of each cycle, for six cycles. The primary endpoint was progression-free survival between the two combination-therapy groups, assessed by independent review committee. Crossover to acalabrutinib was allowed in patients who progressed on obinutuzumab-chlorambucil. Safety was assessed in all patients who received at least one dose of treatment. Enrolment for this trial is complete, and the study is registered at ClinicalTrials.gov, NCT02475681. Findings Between Sept 14, 2015, and Feb 8, 2017, we recruited 675 patients for assessment. 140 patients did not meet eligibility criteria, and 535 patients were randomly assigned to treatment. 179 patients were assigned to receive acalabrutinib-obinutuzumab, 179 patients were assigned to receive acalabrutinib monotherapy, and 177 patients were assigned to receive obinutuzumab-chlorambucil. At median follow-up of 28·3 months (IQR 25·6–33·1), median progression-free survival was longer with acalabrutinib-obinutuzumab and acalabrutinib monotherapy, compared with obinutuzumab-chlorambucil (median not reached with acalabrutinib and obinutuzumab vs 22·6 months with obinutuzumab, hazard ratio [HR] 0·1; 95% CI 0·06–0·17, p<0·0001; and not reached with acalabrutinib monotherapy vs 22·6 months with obinutuzumab, 0·20; 0·13–0·3, p<0·0001). Estimated progression-free survival at 24 months was 93% with acalabrutinib-obinutuzumab (95% CI 87–96%), 87% with acalabrutinib monotherapy (81–92%), and 47% with obinutuzumab-chlorambucil (39–55%). The most common grade 3 or higher adverse event across groups was neutropenia (53 [30%] of 178 patients in the acalabrutinib-obinutuzumab group, 17 [10%] of 179 patients in the acalabrutinib group, and 70 [41%] of 169 patients in the obinutuzumab-chlorambucil group). All-grade infusion reactions were less frequent with acalabrutinib-obinutuzumab (24 [14%] of 178 patients) than obinutuzumab-chlorambucil (67 [40%] of 169 patients). Grade 3 or higher infections occurred in 37 (21%) patients given acalabrutinib-obinutuzumab, 25 (14%) patients given acalabrutinib monotherapy, and 14 (8%) patients given obinutuzumab-chlorambucil. Deaths occurred in eight (5%) patients given acalabrutinib-obinutuzumab, 12 (7%) patients given acalabrutinib, and 15 (9%) patients given obinutuzumab-chlorambucil. Interpretation Acalabrutinib with or without obinutuzumab significantly improved progression-free survival over obinutuzumab-chlorambucil chemoimmunotherapy, providing a chemotherapy-free treatment option with an acceptable side-effect profile that was consistent with previous studies. These data support the use of acalabrutinib in combination with obinutuzumab or alone as a new treatment option for patients with treatment-naive symptomatic chronic lymphocytic leukaemia. Funding Acerta Pharma, a member of the AstraZeneca Group, and R35 CA198183 (to JCB). Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukaemia. ELEVATE-TN is a global, phase 3, multicentre, open-label study in patients with treatment-naive chronic lymphocytic leukaemia done at 142 academic and community hospitals in 18 countries. Eligible patients had untreated chronic lymphocytic leukaemia and were aged 65 years or older, or older than 18 years and younger than 65 years with creatinine clearance of 30–69 mL/min (calculated by use of the Cockcroft-Gault equation) or Cumulative Illness Rating Scale for Geriatrics score greater than 6. Additional criteria included an Eastern Cooperative Oncology Group performance status score of 2 or less and adequate haematologic, hepatic, and renal function. Patients with significant cardiovascular disease were excluded, and concomitant treatment with warfarin or equivalent vitamin K antagonists was prohibited. Patients were randomly assigned (1:1:1) centrally via an interactive voice or web response system to receive acalabrutinib and obinutuzumab, acalabrutinib monotherapy, or obinutuzumab and oral chlorambucil. Treatments were administered in 28-day cycles. To reduce infusion-related reactions, acalabrutinib was administered for one cycle before obinutuzumab administration. Oral acalabrutinib was administered (100 mg) twice a day until progressive disease or unacceptable toxic effects occurred. In the acalabrutinib-obinutuzumab group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 2 and on day 1 (1000 mg) of cycles 3–7. In the obinutuzumab-chlorambucil group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 1 and on day 1 (1000 mg) of cycles 2–6. Oral chlorambucil was given (0·5 mg/kg) on days 1 and 15 of each cycle, for six cycles. The primary endpoint was progression-free survival between the two combination-therapy groups, assessed by independent review committee. Crossover to acalabrutinib was allowed in patients who progressed on obinutuzumab-chlorambucil. Safety was assessed in all patients who received at least one dose of treatment. Enrolment for this trial is complete, and the study is registered at ClinicalTrials.gov, NCT02475681. Between Sept 14, 2015, and Feb 8, 2017, we recruited 675 patients for assessment. 140 patients did not meet eligibility criteria, and 535 patients were randomly assigned to treatment. 179 patients were assigned to receive acalabrutinib-obinutuzumab, 179 patients were assigned to receive acalabrutinib monotherapy, and 177 patients were assigned to receive obinutuzumab-chlorambucil. At median follow-up of 28·3 months (IQR 25·6–33·1), median progression-free survival was longer with acalabrutinib-obinutuzumab and acalabrutinib monotherapy, compared with obinutuzumab-chlorambucil (median not reached with acalabrutinib and obinutuzumab vs 22·6 months with obinutuzumab, hazard ratio [HR] 0·1; 95% CI 0·06–0·17, p<0·0001; and not reached with acalabrutinib monotherapy vs 22·6 months with obinutuzumab, 0·20; 0·13–0·3, p<0·0001). Estimated progression-free survival at 24 months was 93% with acalabrutinib-obinutuzumab (95% CI 87–96%), 87% with acalabrutinib monotherapy (81–92%), and 47% with obinutuzumab-chlorambucil (39–55%). The most common grade 3 or higher adverse event across groups was neutropenia (53 [30%] of 178 patients in the acalabrutinib-obinutuzumab group, 17 [10%] of 179 patients in the acalabrutinib group, and 70 [41%] of 169 patients in the obinutuzumab-chlorambucil group). All-grade infusion reactions were less frequent with acalabrutinib-obinutuzumab (24 [14%] of 178 patients) than obinutuzumab-chlorambucil (67 [40%] of 169 patients). Grade 3 or higher infections occurred in 37 (21%) patients given acalabrutinib-obinutuzumab, 25 (14%) patients given acalabrutinib monotherapy, and 14 (8%) patients given obinutuzumab-chlorambucil. Deaths occurred in eight (5%) patients given acalabrutinib-obinutuzumab, 12 (7%) patients given acalabrutinib, and 15 (9%) patients given obinutuzumab-chlorambucil. Acalabrutinib with or without obinutuzumab significantly improved progression-free survival over obinutuzumab-chlorambucil chemoimmunotherapy, providing a chemotherapy-free treatment option with an acceptable side-effect profile that was consistent with previous studies. These data support the use of acalabrutinib in combination with obinutuzumab or alone as a new treatment option for patients with treatment-naive symptomatic chronic lymphocytic leukaemia." @default.
• W3016538158 created "2020-04-24" @default.
• W3016538158 creator A5000537427 @default.
• W3016538158 creator A5000921376 @default.
• W3016538158 creator A5000959540 @default.
• W3016538158 creator A5004152600 @default.
• W3016538158 creator A5006096720 @default.
• W3016538158 creator A5007254355 @default.
• W3016538158 creator A5010673295 @default.
• W3016538158 creator A5012590429 @default.
• W3016538158 creator A5013007045 @default.
• W3016538158 creator A5014241029 @default.
• W3016538158 creator A5015131529 @default.
• W3016538158 creator A5016426595 @default.
• W3016538158 creator A5016818736 @default.
• W3016538158 creator A5023390126 @default.
• W3016538158 creator A5029736763 @default.
• W3016538158 creator A5029935496 @default.
• W3016538158 creator A5036736992 @default.
• W3016538158 creator A5040412322 @default.
• W3016538158 creator A5046659441 @default.
• W3016538158 creator A5046983883 @default.
• W3016538158 creator A5050633601 @default.
• W3016538158 creator A5055086899 @default.
• W3016538158 creator A5069303553 @default.
• W3016538158 creator A5071804123 @default.
• W3016538158 creator A5086354986 @default.
• W3016538158 creator A5087424125 @default.
• W3016538158 creator A5087770514 @default.
• W3016538158 creator A5087877679 @default.
• W3016538158 creator A5089428686 @default.
• W3016538158 date "2020-04-01" @default.
• W3016538158 modified "2023-10-09" @default.
• W3016538158 title "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial" @default.
• W3016538158 cites W2008650271 @default.
• W3016538158 cites W2022401246 @default.
• W3016538158 cites W2058370462 @default.
• W3016538158 cites W2120319857 @default.
• W3016538158 cites W2129358485 @default.
• W3016538158 cites W2134645992 @default.
• W3016538158 cites W2140606816 @default.
• W3016538158 cites W2142099365 @default.
• W3016538158 cites W2143766748 @default.
• W3016538158 cites W2163709153 @default.
• W3016538158 cites W2163923077 @default.
• W3016538158 cites W2233614027 @default.
• W3016538158 cites W2337485820 @default.
• W3016538158 cites W2396328865 @default.
• W3016538158 cites W2705118184 @default.
• W3016538158 cites W2787916641 @default.
• W3016538158 cites W2789078984 @default.
• W3016538158 cites W2789426966 @default.
• W3016538158 cites W2886452066 @default.
• W3016538158 cites W2888047356 @default.
• W3016538158 cites W2902484351 @default.
• W3016538158 cites W2902706178 @default.
• W3016538158 cites W2908507733 @default.
• W3016538158 cites W2948436219 @default.
• W3016538158 cites W2961471425 @default.
• W3016538158 cites W2964876593 @default.
• W3016538158 cites W2966190920 @default.
• W3016538158 cites W4235474157 @default.
• W3016538158 doi "https://doi.org/10.1016/s0140-6736(20)30262-2" @default.
• W3016538158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8151619" @default.
• W3016538158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32305093" @default.
• W3016538158 hasPublicationYear "2020" @default.
• W3016538158 type Work @default.
• W3016538158 sameAs 3016538158 @default.
• W3016538158 citedByCount "355" @default.
• W3016538158 countsByYear W30165381582020 @default.
• W3016538158 countsByYear W30165381582021 @default.
• W3016538158 countsByYear W30165381582022 @default.
• W3016538158 countsByYear W30165381582023 @default.
• W3016538158 crossrefType "journal-article" @default.
• W3016538158 hasAuthorship W3016538158A5000537427 @default.
• W3016538158 hasAuthorship W3016538158A5000921376 @default.
• W3016538158 hasAuthorship W3016538158A5000959540 @default.
• W3016538158 hasAuthorship W3016538158A5004152600 @default.
• W3016538158 hasAuthorship W3016538158A5006096720 @default.
• W3016538158 hasAuthorship W3016538158A5007254355 @default.
• W3016538158 hasAuthorship W3016538158A5010673295 @default.
• W3016538158 hasAuthorship W3016538158A5012590429 @default.
• W3016538158 hasAuthorship W3016538158A5013007045 @default.
• W3016538158 hasAuthorship W3016538158A5014241029 @default.
• W3016538158 hasAuthorship W3016538158A5015131529 @default.
• W3016538158 hasAuthorship W3016538158A5016426595 @default.
• W3016538158 hasAuthorship W3016538158A5016818736 @default.
• W3016538158 hasAuthorship W3016538158A5023390126 @default.
• W3016538158 hasAuthorship W3016538158A5029736763 @default.
• W3016538158 hasAuthorship W3016538158A5029935496 @default.
• W3016538158 hasAuthorship W3016538158A5036736992 @default.
• W3016538158 hasAuthorship W3016538158A5040412322 @default.
• W3016538158 hasAuthorship W3016538158A5046659441 @default.
• W3016538158 hasAuthorship W3016538158A5046983883 @default.
• W3016538158 hasAuthorship W3016538158A5050633601 @default.
• W3016538158 hasAuthorship W3016538158A5055086899 @default.
• W3016538158 hasAuthorship W3016538158A5069303553 @default.
• W3016538158 hasAuthorship W3016538158A5071804123 @default.

• next